IL37 and acute myeloid leukemia: These include hepatocellular carcinoma, where IL-37 exerted an antiangiogenic role (180) or modulated the phenotype of TAMs by suppressing M2 polarization and regulating proinflammatory cytokine production (181), and Acute Myeloid Leukemia where IL-37 regulated IL-6 expression (182).